Commentary

Video

Challenges With CAR T-Cell Therapies in T-Cell Lymphomas

Author(s):

Jasmine Zain, MD

Jasmine M. Zain, MD, of City of Hope, discuss challenges in CAR-T therapies in patients with T-cell lymphomas.

Jasmine M. Zain, MD, of City of Hope, discuss challenges in CAR-T therapies in patients with T-cell lymphomas.

Related Videos
Andrew Ip, MD
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.
Dasom (Caroline) Lee, MD
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Minoo Battiwalla, MD, MS
Ivy Riano, MD, of Dartmouth Geisel School of Medicine
David C. Fisher, MD
Alex Herrera, MD
Bertram Yuh, MD, MISM, MSHCPM
Grzegorz S. Nowakowski, MD
Related Content
Mantle Cell Lymphoma | stock.adobe.com
December 17th 2024

Glofitamab Produces Durable Remissions in R/R Mantle Cell Lymphoma

Alex F. Herrera, MD, chief, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, associate medical director, Briskin Center for Clinical Research, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
December 13th 2024

Explore Findings With Nivolumab Plus AVD in Advanced-Stage Classic Hodgkin Lymphoma: With Alex F. Herrera, MD

Axi-Cel Sustains Long-Term Efficacy in R/R Follicular Lymphoma and MZL
December 10th 2024

Axi-Cel Sustains Long-Term Efficacy in R/R Follicular Lymphoma and MZL

Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director, Early Phase Therapeutics Program, Systems Clinical Trials Office, co-director, Toni Stephenson Lymphoma Center, professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Nicole Lamanna, MD, associate clinical professor, medicine, Hematologic Malignancies Section, Hematology/Oncology Division, Columbia University Herberg Irving Comprehensive Cancer Center
November 25th 2024

Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MD

Fixed-Duration Epcoritamab Is Active, Safe in Older Newly Diagnosed LBCL
December 10th 2024

Fixed-Duration Epcoritamab Is Active, Safe in Older Newly Diagnosed LBCL

Mantle Cell Lymphoma | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 10th 2024

Brexu-Cel Provides Durable Responses in Relapsed/Refractory, BTK-Naive MCL